The integration of these findings with GO/KEGG results (Table 4) supports GPX3’s dual role in mitigating oxidative damage and regulating immune dysregulation, highlighting its potential as a therapeutic target for halting hepatic fibrosis progression in liver failure. This evidence concerns the gene GPX3 and liver failure.